{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:29:38Z","timestamp":1793478578375,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.pnpbp.2026.111943","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:56:38Z","timestamp":1790434598000},"page":"111943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CYP2C19 and CYP2D6 variation and serotonin reuptake inhibitor outcomes in obsessive-compulsive disorder: a systematic review"],"prefix":"10.1016","volume":"150","author":[{"given":"Shanjida Chowdhury","family":"Ivy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumana","family":"Akther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Abdul","family":"Barek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Shahid","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Shahriar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4924-5319","authenticated-orcid":false,"given":"Mohammad Safiqul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2026.111943_bb0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/a-1288-1061","article-title":"Review and consensus on pharmacogenomic testing in psychiatry","volume":"54","author":"Bousman","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2026.111943_bb0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cpt.2903","article-title":"CPIC guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants","volume":"114","author":"Bousman","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2026.111943_bb0015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/tpj.2013.12","article-title":"Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder","volume":"14","author":"Brandl","year":"2014","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.pnpbp.2026.111943_bb0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41397-022-00267-7","article-title":"Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of participants of the Australian Genetics of Depression Study","volume":"22","author":"Campos","year":"2022","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.pnpbp.2026.111943_bb0025","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00406-005-0573-y","article-title":"Insight and alexithymia in adult outpatients with obsessive-compulsive disorder","volume":"255","author":"De Berardis","year":"2005","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111943_bb0030","article-title":"Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case report","volume":"2012","author":"De Berardis","year":"2012","journal-title":"Case Rep Psychiatry."},{"key":"10.1016\/j.pnpbp.2026.111943_bb0035","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.euroneuro.2018.05.009","article-title":"Effect of CYP2C19 metabolizing activity on antidepressant response and side effects: meta-analysis of data from genome-wide association studies","volume":"28","author":"Fabbri","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111943_bb0040","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.psychres.2014.12.003","article-title":"Obsessive-compulsive disorder: practical strategies for pharmacological and somatic treatment in adults","volume":"227","author":"Fineberg","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2026.111943_bb0045","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/gim.2016.80","article-title":"Prediction of CYP2D6 phenotype from genotype across world populations","volume":"19","author":"Gaedigk","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.pnpbp.2026.111943_bb0050","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-026-08073-2","article-title":"Pharmacogenomic-guided prescribing and polypharmacy across age groups in obsessive-compulsive disorder: a retrospective study","volume":"26","author":"Garrison","year":"2026","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111943_bb0055","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.pnpbp.2026.111943_bb0060","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"CPIC guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2026.111943_bb0065","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0269881111414451","article-title":"CYP2C19 genotype predicts steady-state escitalopram concentration in GENDEP","volume":"26","author":"Huezo-Diaz","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111943_bb0070","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1056\/NEJMcp031002","article-title":"Obsessive-compulsive disorder","volume":"350","author":"Jenike","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2026.111943_bb0075","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1176\/appi.ajp.2017.17050550","article-title":"Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients","volume":"175","author":"Juki\u0107","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111943_bb0080","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41398-020-01129-1","article-title":"Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19","volume":"11","author":"Koopmans","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111943_bb0085","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/jamapsychiatry.2020.3643","article-title":"Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis","volume":"78","author":"Milosavljevic","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111943_bb0090","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/gtmb.2011.0327","article-title":"The AmpliChip CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism","volume":"16","author":"M\u00fcller","year":"2012","journal-title":"Genet. Test. Mol. Biomarkers"},{"key":"10.1016\/j.pnpbp.2026.111943_bb0095","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.pnpbp.2026.111943_bb0100","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1017\/S1461145702002900","article-title":"Treatment non-response in OCD: methodological issues and operational definitions","volume":"5","author":"Pallanti","year":"2002","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111943_bb0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication","volume":"15","author":"Ruscio","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111943_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/ph15070870","article-title":"Clinical impact of functional CYP2C19 and CYP2D6 variants on antidepressant treatment in young people with depression","volume":"15","author":"Thiele","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.pnpbp.2026.111943_bb0115","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/13651500902903016","article-title":"Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms","volume":"13","author":"Van Nieuwerburgh","year":"2009","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.pnpbp.2026.111943_bb0120","series-title":"The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses","author":"Wells","year":"2026"},{"key":"10.1016\/j.pnpbp.2026.111943_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/ph16091277","article-title":"Effects of CYP2C19 genotype on proxies of SSRI antidepressant response in the UK Biobank","volume":"16","author":"Wong","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.pnpbp.2026.111943_bb0130","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2217\/pgs.14.83","article-title":"Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians","volume":"15","author":"Zai","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pnpbp.2026.111943_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2025.111315","article-title":"Pharmacogenetics of obsessive-compulsive disorder: investigations of intragenic and regulatory region genetic variations","volume":"138","author":"Zai","year":"2025","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626003416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626003416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:38:25Z","timestamp":1793475505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584626003416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":27,"alternative-id":["S0278584626003416"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111943","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP2C19 and CYP2D6 variation and serotonin reuptake inhibitor outcomes in obsessive-compulsive disorder: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111943"}}